Ovarian stimulation and oocyte quality

Yakovlev P.P.; Kogan I.Yu.

doi:https://doi.org/10.17116/repro20222803186

Close metadata

Recommended articles:

Age-related peculiarities of blood parameters in women and their impact on the outcome of in vitro fertilization programs. Russian Journal of Human Reproduction. 2025;(2):28-36

Visualization of the mitotic spindle in oocytes of patients with ovarian endometriosis as a prognostic factor for the effectiveness of fertilization and early embryonic development in IVF/ICSI programs. Russian Journal of Human Reproduction. 2025;(3):55-62

Influence of carriage of papillomavirus infection on the course of external genital endometriosis in patients with intraepithelial lesion of the cervix. Russian Journal of Human Reproduction. 2025;(3):77-83

Experimental modeling and treatment of endometriosis using bovhyaluronidase azoximer in an animal model. Russian Journal of Human Reproduction. 2025;(4):26-40

The Paternity Test. Russian Journal of Human Reproduction. 2025;(4):41-45

Extracellular vesicles and their role in endometrial receptivity in patients with recurrent implantation failure. Russian Journal of Human Reproduction. 2025;(4):46-52

The dependence of the ploidic status of embryos on the state of the spindle of oocyte division, assessed using polarization microscopy in IVF programs in women with ovarian endometriosis. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):44-49

Primary ovarian insufficiency: opportunities and prospects for the realization of reproductive function. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):42-47

The role of pelvic inflammatory diseases in reproductive function disorders in women. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):48-54

Characteristics of factors contributing to disorders of reproductive function in patients with adenomyosis. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):68-74

Abstract:

Ovarian stimulation (OS) affects the clinical outcomes of assisted reproductive technologies (ART). The number of oocytes obtained during IVF may depend on the protocols of ovarian stimulation, the dosage of gonadotropins and the duration of stimulation. However, the impact of OS on the quality of oocytes and embryos is still unclear. In this review, we considered the main aspects of the possible impact of pre-treatment and adjuvant therapy, OS protocols, the time of starting the administration of gonadotropins, dosages, types of gonadotropins, duration of OS, types of trigger used for the final maturation of oocytes, the follicle diameter and the time of transvaginal follicle puncture on the quality of obtained oocytes and clinical outcomes of ART cycles. In this review, we considered the main aspects of the possible impact of pre-treatment and adjuvant therapy, OS protocols, the time of the start of gonadotropin administration, dosages, types of gonadotropins, OS duration, types of trigger used for final maturation of oocytes, follicle diameter and time of oocyte pick up on the quality of the obtained oocytes and clinical outcomes of IVF cycles.

Keywords:

oocyte quality

ovarian stimulation

IVF

infertility

Authors:

Yakovlev P.P.

Centre for Reproductive Medicine Co. Ltd. «Next Generation Clinic»

Kogan I.Yu.

Ott Scientific Research Institute of Obstetrics, Gynecology and Reproductology;
St. Petersburg State University

Received:

12.08.2021

Accepted:

17.04.2022

Close metadata

References:

Russell DL, Salustri A. Extracellular matrix of the cumulus-oocyte complex. Seminars in Reproductive Medicine. 2006;24(4):217-227. https://doi.org/10.1055/s-2006-948551
Qassem E, Falah K, Aghaways I, Salih T. A correlative study of oocytes morphology with fertilization, cleavage, embryo quality and implantation rates after intra cytoplasmic sperm injection. Acta Medica International. 2015;2:7-13. https://doi.org/10.5530/ami.2015.1.3
Picinato MC, Martins WP, Giorgenon RC, Santos CK, Ferriani RA, Navarro PA, de Sá Rosa-e-Silva AC. The impact of examining the meiotic spindle by polarization microscopy on assisted reproduction outcomes. Fertility and Sterility. 2014;101(2):379-384. https://doi.org/10.1016/j.fertnstert.2013.10.009
Swiatecka J, Bielawski T, Anchim T, Leśniewska M, Milewski R, Wołczyński S. Oocyte zona pellucida and meiotic spindle birefringence as a biomarker of pregnancy rate outcome in IVF-ICSI treatment. Ginekologia Polska. 2014;85(4):264-271. https://doi.org/10.17772/gp/1722
Halvaei I, Khalili MA, Soleimani M, Razi MH. Evaluating the Role of First Polar Body Morphology on Rates of Fertilization and Embryo Development in ICSI Cycles. International Journal of Fertility and Sterility. 2011;5(2):110-115.
Cheng EH, Chen SU, Lee TH, Pai YP, Huang LS, Huang CC, Lee MS. Evaluation of telomere length in cumulus cells as a potential biomarker of oocyte and embryo quality. Human Reproduction. 2013; 28(4):929-936. https://doi.org/10.1093/humrep/det004
Butts S, Riethman H, Ratcliffe S, Shaunik A, Coutifaris C, Barnhart K. Correlation of telomere length and telomerase activity with occult ovarian insufficiency. The Journal of Clinical Endocrinology and Metabolism. 2009;94(12):4835-4843. https://doi.org/10.1210/jc.2008-2269
Ekart J, McNatty K, Hutton J, Pitman J. Ranking and selection of MII oocytes in human ICSI cycles using gene expression levels from associated cumulus cells. Human Reproduction. 2013;28(11):2930-2942. https://doi.org/10.1093/humrep/det357
Burnik Papler T, Vrtacnik Bokal E, Lovrecic L, Kopitar AN, Maver A. No specific gene expression signature in human granulosa and cumulus cells for prediction of oocyte fertilisation and embryo implantation. PLoS One. 2015;13;10(3):e0115865. https://doi.org/10.1371/journal.pone.0115865
Fischer NM, Nguyen HV, Singh B, Baker VL, Segars JH. Prognostic value of oocyte quality in assisted reproductive technology outcomes: a systematic review. F&S Reviews. 2021;2:120-139. https://doi.org/10.1016/j.xfnr.2021.03.001
ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine. Electronic address: https://doi.org/10.1016/j.rbmo.2017.06.015
Lemmen JG, Rodríguez NM, Andreasen LD, Loft A, Ziebe S. The total pregnancy potential per oocyte aspiration after assisted reproduction-in how many cycles are biologically competent oocytes available? Journal of Assisted Reproduction and Genetics. 2016;33(7): 849-854. https://doi.org/10.1007/s10815-016-0707-3
Tatone C. Oocyte senescence: a firm link to age-related female subfertility. Gynecological Endocrinology. 2008;24(2):59-63. https://doi.org/10.1080/09513590701733504
Farquhar C, Rombauts L, Kremer JA, Lethaby A, Ayeleke RO. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. The Cochrane Database of Systematic Reviews. 2017; 5(5):CD006109. https://doi.org/10.1002/14651858.CD006109.pub3
Martínez F, Boada M, Coroleu B, Clua E, Parera N, Rodríguez I, Barri PN. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH. Human Reproduction. 2006;21(8):2121-2125. https://doi.org/10.1093/humrep/del121
Barad DH, Kim A, Kubba H, Weghofer A, Gleicher N. Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? A pilot study. Reproductive Biology and Endocrinology: RB&E. 2013;11:28. https://doi.org/10.1186/1477-7827-11-28
Ovarian Stimulation TEGGO, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, Kunicki M, La Marca A, Lainas G, Le Clef N, Massin N, Mastenbroek S, Polyzos N, Sunkara SK, Timeva T, Töyli M, Urbancsek J, Vermeulen N, Broekmans F. ESHRE guideline: ovarian stimulation for IVF/ICSI†. Human Reproduction Open. 2020;2020(2):hoaa009. https://doi.org/10.1093/hropen/hoaa009
Shahrokh Tehrani Nejad E, Bakhtiari Ghaleh F, Eslami B, Haghollahi F, Bagheri M, Masoumi M. Comparison of pre-treatment with OCPs or estradiol valerate vs. no pre-treatment prior to GnRH antagonist used for IVF cycles: An RCT. International Journal of Reproductive Biomedicine. 2018;16(8):535-540.
Boots CE, Meister M, Cooper AR, Hardi A, Jungheim ES. Ovarian stimulation in the luteal phase: systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics. 2016;33(8): 971-980. https://doi.org/10.1007/s10815-016-0721-5
Pereira N, Voskuilen-Gonzalez A, Hancock K, Lekovich JP, Schattman GL, Rosenwaks Z. Random-start ovarian stimulation in women desiring elective cryopreservation of oocytes. Reproductive Biomedicine Online. 2017;35(4):400-406. https://doi.org/10.1016/j.rbmo.2017.06.002
Siristatidis CS, Gibreel A, Basios G, Maheshwari A, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. The Cochrane Database of Systematic Reviews. 2015;(11):CD006919. https://doi.org/10.1002/14651858.CD006919.pub4
Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Human Reproduction. 2007;22(11): 2805-2813. https://doi.org/10.1093/humrep/dem270
Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, van der Veen F, van Wely M. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Human Reproduction Update. 2017;23(5): 560-579. https://doi.org/10.1093/humupd/dmx017
Lin Y, Yang P, Chen Y, Zhu J, Zhang X, Ma C. Factors inducing decreased oocyte maturation rate: a retrospective analysis of 20,939 ICSI cycles. Archives of Gynecology and Obstetrics. 2019;299(2): 559-564. https://doi.org/10.1007/s00404-018-4958-3
Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews. 2016;4(4):CD001750. https://doi.org/10.1002/14651858.CD001750.pub4
Ata B, Capuzzo M, Turkgeldi E, Yildiz S, La Marca A. Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses. Human Reproduction Update. 2021;27(1):48-66. https://doi.org/10.1093/humupd/dmaa040
Jeppesen JV, Kristensen SG, Nielsen ME, Humaidan P, Dal Canto M, Fadini R, Schmidt KT, Ernst E, Yding Andersen C. LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles. The Journal of Clinical Endocrinology and Metabolism. 2012;97(8):1524-1531. https://doi.org/10.1210/jc.2012-1427
Witz CA, Daftary GS, Doody KJ, Park JK, Seifu Y, Yankov VI, Heiser PW; Menopur in GnRH Antagonist Cycles with Single Embryo Transfer — High Responder (MEGASET-HR) Trial Group. Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. Fertility and Sterility. 2020;114(2):321-330. https://doi.org/10.1016/j.fertnstert.2020.03.029
Filicori M, Cognigni GE, Tabarelli C, Pocognoli P, Taraborrelli S, Spettoli D, Ciampaglia W. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. The Journal of Clinical Endocrinology and Metabolism. 2002;87(3): 1156-1161. https://doi.org/10.1210/jcem.87.3.8322
Santi D, Casarini L, Alviggi C, Simoni M. Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the «Personalized» Medicine Era: A Meta-analysis. Frontiers in Endocrinology. 2017;8:114. https://doi.org/10.3389/fendo.2017.00114
Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, Bühler K, Ferraretti AP, De Placido G, Mollo A, Fischer R, Humaidan P; International Collaborative Group for the Study of r-hLH (iCOS-LH). Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertility and Sterility. 2018;109(4):644-664. https://doi.org/10.1016/j.fertnstert.2018.01.003
van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. The Cochrane Database of Systematic Reviews. 2011;2011(2):CD005354. https://doi.org/10.1002/14651858.CD005354.pub2
Mochtar MH, Danhof NA, Ayeleke RO, Van der Veen F, van Wely M. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane Database of Systematic Reviews. 2017;5(5): CD005070. https://doi.org/10.1002/14651858.CD005070.pub3
Chua SJ, Mol BW, Longobardi S, Orvieto R, Venetis CA, Lispi M, Storr A, D’Hooghe T. Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis. Reproductive Biology and Endocrinology: RB&E. 2021;19(1):51. https://doi.org/10.1186/s12958-021-00727-y
Orvieto R, Seifer DB. Biosimilar FSH preparations- are they identical twins or just siblings? Reproductive Biology and Endocrinology: RB&E. 2016;14(1):32. https://doi.org/10.1186/s12958-016-0167-8
Bergandi L, Canosa S, Carosso AR, Paschero C, Gennarelli G, Silvagno F, Benedetto C, Revelli A. Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization. Pharmaceuticals (Basel). 2020;13(7):136. https://doi.org/10.3390/ph13070136
Huber M, Hadziosmanovic N, Berglund L, Holte J. Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem. Fertility and Sterility. 2013;100(5):1270-1276. https://doi.org/10.1016/j.fertnstert.2013.06.049
Weghofer A, Barad DH, Darmon SK, Kushnir VA, Albertini DF, Gleicher N. The ovarian sensitivity index is predictive of live birth chances after IVF in infertile patients. Human Reproduction Open. 2020;2020(4):hoaa049. https://doi.org/10.1093/hropen/hoaa049
Gonullu DC, McCulloh DH, Robinson LG Jr, Oh C, Keefe DL. Oocyte stimulation parameters influence the number and proportion of mature oocytes retrieved in assisted reproductive technology cycles. Journal of Assisted Reproduction and Genetics. 2021;38(9): 2283-2289. https://doi.org/10.1007/s10815-021-02220-2
Clark ZL, Thakur M, Leach RE, Ireland JJ. FSH dose is negatively correlated with number of oocytes retrieved: analysis of a data set with ~650,000 ART cycles that previously identified an inverse relationship between FSH dose and live birth rate. Journal of Assisted Reproduction and Genetics. 2021;38(7):1787-1797. https://doi.org/10.1007/s10815-021-02179-0
Bosch E, Valencia I, Escudero E, Crespo J, Simón C, Remohí J, Pellicer A. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertility and Sterility. 2003;80(6):1444-1449. https://doi.org/10.1016/j.fertnstert.2003.07.002
Karl KR, Jimenez-Krassel F, Gibbings E, Ireland JLH, Clark ZL, Tempelman RJ, Latham KE, Ireland JJ. Negative impact of high doses of follicle-stimulating hormone during superovulation on the ovulatory follicle function in small ovarian reserve dairy heifers. Biology of Reproduction. 2021;104(3):695-705. https://doi.org/10.1093/biolre/ioaa210
Roberts R, Iatropoulou A, Ciantar D, Stark J, Becker DL, Franks S, Hardy K. Follicle-stimulating hormone affects metaphase I chromosome alignment and increases aneuploidy in mouse oocytes matured in vitro. Biology of Reproduction. 2005;72(1):107-118. https://doi.org/10.1095/biolreprod.104.032003
Barash OO, Hinckley MD, Rosenbluth EM, Ivani KA, Weckstein LN. High gonadotropin dosage does not affect euploidy and pregnancy rates in IVF PGS cycles with single embryo transfer. Human Reproduction. 2017;32(11):2209-2217. https://doi.org/10.1093/humrep/dex299
Wu Q, Li H, Zhu Y, Jiang W, Lu J, Wei D, Yan J, Chen ZJ. Dosage of exogenous gonadotropins is not associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women. Human Reproduction. 2018;33(10):1875-1882. https://doi.org/10.1093/humrep/dey270
Irani M, Canon C, Robles A, Maddy B, Gunnala V, Qin X, Zhang C, Xu K, Rosenwaks Z. No effect of ovarian stimulation and oocyte yield on euploidy and live birth rates: an analysis of 12 298 trophectoderm biopsies. Human Reproduction. 2020;35(5):1082-1089. https://doi.org/10.1093/humrep/deaa028
Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Human Reproduction. 2005;20(5): 1213-1220. https://doi.org/10.1093/humrep/deh765
Zelinski-Wooten MB, Hutchison JS, Hess DL, Wolf DP, Stouffer RL. A bolus of recombinant human follicle stimulating hormone at midcycle induces periovulatory events following multiple follicular development in macaques. Human Reproduction. 1998;13(3): 554-560. https://doi.org/10.1093/humrep/13.3.554
Lamb JD, Shen S, McCulloch C, Jalalian L, Cedars MI, Rosen MP. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility. 2011;95(5):1655-1660. https://doi.org/10.1016/j.fertnstert.2011.01.019
Cimadomo D, Vaiarelli A, Petriglia C, Fabozzi G, Ferrero S, Schimberni M, Argento C, Colamaria S, Giuliani M, Ubaldi N, Rienzi L, Ubaldi FM. Oocyte competence is independent of the ovulation trigger adopted: a large observational study in a setting that entails vitrified-warmed single euploid blastocyst transfer. Journal of Assisted Reproduction and Genetics. 2021;38(6):1419-1427. https://doi.org/10.1007/s10815-021-02124-1
Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction. 2005;20(10): 2887-2892. https://doi.org/10.1093/humrep/dei150
Galindo A, Bodri D, Guillen JJ, Colodron M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecological Endocrinology. 2009;25(1):60-66. https://doi.org/10.1080/09513590802404013
Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, Pellicer A, Remohí J. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reproductive Biomedicine Online. 2009; 19(4):486-492. https://doi.org/10.1016/j.rbmo.2009.06.001
Mizrachi Y, Horowitz E, Farhi J, Raziel A, Weissman A. Ovarian stimulation for freeze-all IVF cycles: a systematic review. Human Reproduction Update. 2020;26(1):118-135. https://doi.org/10.1093/humupd/dmz037
Castillo JC, Moreno J, Dolz M, Bonilla-Musoles F. Successful Pregnancy Following Dual Triggering Concept (rhCG + GnRH Agonist) in a Patient Showing Repetitive Inmature Oocytes and Empty Follicle Syndrome: Case Report. Journal of Medical Cases. 2013;5: 221-226.
Griffin D, Feinn R, Engmann L, Nulsen J, Budinetz T, Benadiva C. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates. Fertility and Sterility. 2014;102(2):405-409. https://doi.org/10.1016/j.fertnstert.2014.04.028
Nogueira D, Friedler S, Schachter M, Raziel A, Ron-El R, Smitz J. Oocyte maturity and preimplantation development in relation to follicle diameter in gonadotropin-releasing hormone agonist or antagonist treatments. Fertility and Sterility. 2006;85(3):578-583. https://doi.org/10.1016/j.fertnstert.2005.08.033
Scott RT, Hofmann GE, Muasher SJ, Acosta AA, Kreiner DK, Rosenwaks Z. Correlation of follicular diameter with oocyte recovery and maturity at the time of transvaginal follicular aspiration. Journal of in Vitro Fertilization and Embryo Transfer: IVF. 1989;6(2):73-75. https://doi.org/10.1007/BF01130729
Wirleitner B, Okhowat J, Vištejnová L, Králíčková M, Karlíková M, Vanderzwalmen P, Ectors F, Hradecký L, Schuff M, Murtinger M. Relationship between follicular volume and oocyte competence, blastocyst development and live-birth rate: optimal follicle size for oocyte retrieval. Ultrasound in Obstetrics and Gynecology. 2018;51(1): 118-125. https://doi.org/10.1002/uog.18955
McCulloh DH, Kutchukhidze N, Charkviani T, Zhorzholadze T, Barbakadze T, Munné S, Chkonia L. Follicle size indicates oocyte maturity and blastocyst formation but not blastocyst euploidy following controlled ovarian hyperstimulation of oocyte donors. Human Reproduction. 2020;35(3):545-556. https://doi.org/10.1093/humrep/dez291
Weiss A, Neril R, Geslevich J, Lavee M, Beck-Fruchter R, Golan J, Shalev E. Lag time from ovulation trigger to oocyte aspiration and oocyte maturity in assisted reproductive technology cycles: a retrospective study. Fertility and Sterility. 2014;102(2):419-423. https://doi.org/10.1016/j.fertnstert.2014.04.041
Bosdou JK, Kolibianakis EM, Venetis CA, Zepiridis L, Chatzimeletiou K, Makedos A, Triantafyllidis S, Masouridou S, Mitsoli A, Tarlatzis B. Is the time interval between HCG administration and oocyte retrieval associated with oocyte retrieval rate? Reproductive Biomedicine Online. 2015;31(5):625-632. https://doi.org/10.1016/j.rbmo.2015.08.005
Azizi E, Naji M, Nazarian H, Salehpour S, Karimi M, Borumandnia N, Shams Mofarahe Z. Correction to: Does timing in ICSI cycle affect oocyte quality and reproductive outcomes? A prospective study. Archives of Gynecology and Obstetrics. 2020;302(2):515-518. https://doi.org/10.1007/s00404-020-05613-3
Hu KL, Ye X, Wang S, Zhang D. Melatonin Application in Assisted Reproductive Technology: A Systematic Review and Meta-Analysis of Randomized Trials. Frontiers in Endocrinology. 2020;27;11:160. https://doi.org/10.3389/fendo.2020.00160
Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. The Cochrane Database of Systematic Reviews. 2014;18;2014(11):CD006105. https://doi.org/10.1002/14651858.CD006105.pub3
Li XL, Wang L, Lv F, Huang XM, Wang LP, Pan Y, Zhang XM. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(12):e6443. https://doi.org/10.1097/MD.0000000000006443
Siristatidis CS, Basios G, Pergialiotis V, Vogiatzi P. Aspirin for in vitro fertilisation. The Cochrane Database of Systematic Reviews. 2016;11(11):CD004832. https://doi.org/10.1002/14651858.CD004832.pub4
Ataalla W, Elhamid T, Elhalwagy A. Adjuvant sildenafil therapy in poor responders undergoing in vitro fertilization: a prospective, randomized, double-blind, placebo-controlled trial. Middle East Fertility Society Journal. 2016;21(3);175-179. https://doi.org/10.1016/j.mefs.2015.12.004